Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer

Reuters

09/05

Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer

Roche Holding AG has announced that it has received CE IVDR approval for two label expansions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. This test is now approved to assist in the identification of metastatic breast cancer patients with HER2-ultralow status, making them potentially eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca. Additionally, the test is approved for identifying patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with ZIIHERA® (zanidatamab-hrii) by Jazz Pharmaceuticals. Roche's expanded approval aims to enhance personalized treatment options for patients facing challenging cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: SF65914) on September 05, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2565395015"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565395015\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565395015?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565395015","market":"us","top_or_hot":-1,"title":"Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Roche Holding AG has announced that it has received CE IVDR approval for two label expansions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. This test is now approved to assist in the identification of metastatic breast cancer patients with HER2-ultralow status, making them potentially eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate developed by <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> and AstraZeneca. Additionally, the test is approved for identifying patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with ZIIHERA® (zanidatamab-hrii) by Jazz Pharmaceuticals. Roche's expanded approval aims to enhance personalized treatment options for patients facing challenging cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: SF65914) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-05 13:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Roche Holding AG has announced that it has received CE IVDR approval for two label expansions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. This test is now approved to assist in the identification of metastatic breast cancer patients with HER2-ultralow status, making them potentially eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate developed by <a href=\"https://laohu8.com/S/DSKY\">Daiichi Sankyo</a> and AstraZeneca. Additionally, the test is approved for identifying patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with ZIIHERA® (zanidatamab-hrii) by Jazz Pharmaceuticals. Roche's expanded approval aims to enhance personalized treatment options for patients facing challenging cancers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: SF65914) on September 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0976567544.SGD","symbol_name":"FTIF - Templeton Global Income A Mdis SGD-H1","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nNDL5m38ZQ:1","article_id":"2565395015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565395015","pubTimestamp":1757048424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2  Diagnostic Test in Breast and Biliary Tract Cancer. Roche Holding AG has announced that it has received CE IVDR approval for two label expansions of its VENTANA HER2  Rabbit Monoclonal Primary Antibody RxDx* assay. This test is now approved to assist in the identification of metastatic breast cancer patients with HER2-ultralow status, making them potentially eligible for treatment with ENHERTU , a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca. Additionally, the test is approved for identifying patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with ZIIHERA  by Jazz Pharmaceuticals. Roche's expanded approval aims to enhance personalized treatment options for patients facing challenging cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0047473722.EUR":"HSBC GIF EUROPE VALUE \"PD\" (EUR) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","JAZZ":"爵士制药","LU0949170426.SGD":"Blackrock Global Multi-Asset Income A6 SGD-H","LU0882574055.USD":"富达全球健康医疗A ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1003076772.USD":"BGF EUROPEAN EQUITY INCOME \"A5G\" (USDHDG) INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0823399737.USD":"BNP PARIBAS EUROPE EQUITY \"C\" (USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0972486137.USD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AUH\" (USDHDG) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","AZN.UK":"阿斯利康制药","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","LU0345777659.USD":"NINETY ONE GSF EUROPEAN EQUITY \"A\" (USD) INC","LU0969580561.USD":"贝莱德欧洲特别时机基金A2","LU1019634622.SGD":"Blackrock European Equity Income A6 SGD-H","BK5011":"制药","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","LU0047473722.SGD":"HSBC GIF EUROPE VALUE \"PD\" (SGD) INC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","03165":"华夏欧优股对冲","LU0964806797.USD":"UBS (LUX) EQUITY FUND - EUROPEAN OPPORTUNITY SUSTAINABLE (EUR) \"P\" (USHDG) ACC","LU0997586432.USD":"FIDELITY SUSTAINABLE EUROPE EQUITY \"A\" (USDHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0640478417.SGD":"THREADNEEDLE (LUX) PAN EUROPEAN ESG EQUITIES \"AGH\" (SGDHDG) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1880407215.USD":"AMUNDI FUNDS NET ZERO AMBITION TOP EUROPEAN PLAYERS \"A2\" (USD) INC","LU0784383803.USD":"BGF GLOBAL MULTI-ASSET INCOME FUND \"A\" (USD) INC A","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4007":"制药","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0526926950.USD":"贝莱德欧洲基金","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC"},"translate_title":"罗氏控股公司获得CE IVDR批准，扩大VENTANA HER2(4B5)诊断测试在乳腺癌和胆道癌中的使用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"AZN.UK":0.9,"JAZZ":0.9},"content_text":"Roche Holding AG Receives CE IVDR Approval for Expanded Use of VENTANA HER2 (4B5) Diagnostic Test in Breast and Biliary Tract Cancer\n    \n\n        Roche Holding AG has announced that it has received CE IVDR approval for two label expansions of its VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* assay. This test is now approved to assist in the identification of metastatic breast cancer patients with HER2-ultralow status, making them potentially eligible for treatment with ENHERTU® (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca. Additionally, the test is approved for identifying patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer who may be eligible for treatment with ZIIHERA® (zanidatamab-hrii) by Jazz Pharmaceuticals. Roche's expanded approval aims to enhance personalized treatment options for patients facing challenging cancers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: SF65914) on September 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}